thalidomide has been researched along with Sepsis in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Rats were divided randomly into five groups: Sham group, LPS-treated sepsis group, LPS+thalidomide treated group, LPS+etanercept treated group and LPS+thalidomide+etanercept treated group, respectively." | 7.85 | Which one is more effective for the treatment of rat sepsis model: thalidomide or etanercept? ( Bardas, R; Gul, HF; Ilhan, N; Susam, S, 2017) |
| "Thalidomide is an inhibitor of tumour necrosis factor-alpha (TNFalpha) that has been proven effective for the treatment of experimental sepsis by Escherichia coli." | 7.73 | Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study. ( Bolanos, N; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Koussoulas, V; Laoutaris, G; Papadakis, V; Perrea, D, 2005) |
| "Thalidomide, an agent which inhibits biosynthesis of tumor necrosis factor alpha (TNF-alpha) and which is used to treat a variety of chronic inflammatory conditions, was investigated as therapy for experimental sepsis." | 7.72 | Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide. ( Dontas, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Kostomitsopoulos, N; Perrea, D; Poulaki, H, 2003) |
| "the thalidomide-alone treated mice showed 75% survival whereas 60% of the Augmentin-alone treated group survived." | 5.35 | A combination of thalidomide and augmentin protects BALB/c mice suffering from Klebsiella pneumoniae B5055-induced sepsis. ( Chhibber, S; Harjai, K; Kumar, V, 2009) |
| "The aim of this study was to evaluate the therapeutic effects of thalidomide and etanercept on lipopolysaccharide (LPS)-induced sepsis in a rat model." | 3.91 | The therapeutic effects of thalidomide and etanercept on septic rats exposed to lipopolysaccharide. ( Gül, HF; İlhan, N; Susam, S, 2019) |
| " Rats were divided randomly into five groups: Sham group, LPS-treated sepsis group, LPS+thalidomide treated group, LPS+etanercept treated group and LPS+thalidomide+etanercept treated group, respectively." | 3.85 | Which one is more effective for the treatment of rat sepsis model: thalidomide or etanercept? ( Bardas, R; Gul, HF; Ilhan, N; Susam, S, 2017) |
| "Thalidomide is an inhibitor of tumour necrosis factor-alpha (TNFalpha) that has been proven effective for the treatment of experimental sepsis by Escherichia coli." | 3.73 | Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study. ( Bolanos, N; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Koussoulas, V; Laoutaris, G; Papadakis, V; Perrea, D, 2005) |
| "Thalidomide, an agent which inhibits biosynthesis of tumor necrosis factor alpha (TNF-alpha) and which is used to treat a variety of chronic inflammatory conditions, was investigated as therapy for experimental sepsis." | 3.72 | Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide. ( Dontas, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Karayannacos, PE; Kostomitsopoulos, N; Perrea, D; Poulaki, H, 2003) |
| "the thalidomide-alone treated mice showed 75% survival whereas 60% of the Augmentin-alone treated group survived." | 1.35 | A combination of thalidomide and augmentin protects BALB/c mice suffering from Klebsiella pneumoniae B5055-induced sepsis. ( Chhibber, S; Harjai, K; Kumar, V, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ilhan, N | 4 |
| Susam, S | 2 |
| Gul, HF | 2 |
| Bardas, R | 1 |
| Kumar, V | 1 |
| Harjai, K | 1 |
| Chhibber, S | 1 |
| Sullivan, E | 1 |
| Hoyle, C | 1 |
| Lee, CK | 1 |
| Barlogie, B | 1 |
| Zangari, M | 1 |
| Fassas, A | 1 |
| Anaissie, E | 1 |
| Morris, C | 1 |
| Van Rhee, F | 1 |
| Cottler-Fox, M | 1 |
| Thertulien, R | 1 |
| Muwalla, F | 1 |
| Mazher, S | 1 |
| Badros, A | 1 |
| Tricot, G | 1 |
| Wölfler, A | 1 |
| Bauer, F | 1 |
| Zollner, G | 1 |
| Weber, K | 1 |
| Sill, H | 1 |
| Linkesch, W | 1 |
| Giamarellos-Bourboulis, EJ | 2 |
| Poulaki, H | 1 |
| Kostomitsopoulos, N | 1 |
| Dontas, I | 1 |
| Perrea, D | 2 |
| Karayannacos, PE | 2 |
| Giamarellou, H | 2 |
| Bolanos, N | 1 |
| Laoutaris, G | 1 |
| Papadakis, V | 1 |
| Koussoulas, V | 1 |
| Wiedemann, HR | 1 |
| Raza, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| (PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older[NCT01453088] | Phase 2 | 63 participants (Actual) | Interventional | 2010-06-24 | Terminated (stopped due to Lack of Accrual) | ||
| Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma[NCT01241708] | Phase 3 | 146 participants (Actual) | Interventional | 2010-04-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01453088)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 27 |
| Auto Transplant High Dose Melphalan+Bortezomib | 27 |
Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years (NCT01453088)
Timeframe: Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 13 |
| Auto Transplant High Dose Melphalan+Bortezomib | 11 |
1 review available for thalidomide and Sepsis
| Article | Year |
|---|---|
Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.
Topics: Arthritis, Rheumatoid; Crohn Disease; Etanercept; Humans; Immunoglobulin G; Myelodysplastic Syndrome | 2000 |
9 other studies available for thalidomide and Sepsis
| Article | Year |
|---|---|
Which one is more effective for the treatment of rat sepsis model: thalidomide or etanercept?
Topics: Animals; Etanercept; Interleukin-1beta; Male; NF-kappa B; Random Allocation; Rats; Rats, Wistar; Sep | 2017 |
The therapeutic effects of thalidomide and etanercept on septic rats exposed to lipopolysaccharide.
Topics: Animals; Cytokines; Disease Models, Animal; Etanercept; Lipopolysaccharides; Liver; Male; Rats; Rats | 2019 |
A combination of thalidomide and augmentin protects BALB/c mice suffering from Klebsiella pneumoniae B5055-induced sepsis.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Anti-Bacterial Agents; Drug Therapy, Combina | 2009 |
Calciphylaxis, occurring 10 weeks after hypercalcaemia, in a patient with multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arterioles; Calciphylaxis; Chelation Therapy; Cyclop | 2011 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tr | 2002 |
Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Fatal Outcome; Female; Humans; | 2003 |
Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide.
Topics: Animals; Bacteremia; Cytokines; Escherichia coli Infections; Female; Humans; Immunosuppressive Agent | 2003 |
Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Endotoxins; Interferon-gamma; | 2005 |
[Consequences of unexpected drug effects, beginning with contergan studies by pediatrists].
Topics: Abnormalities, Drug-Induced; Acrodynia; Bacterial Infections; Child; Child, Preschool; Chloramphenic | 1981 |